No Data
Takeda (TAK.US) has initiated two Phase 3 clinical trials in china, launching innovative therapies for the disease of "excessive sleep".
TAK-861 is an oral orexin receptor 2 (OX2R) agonist. The product has been previously included in the breakthrough therapy category for the treatment of type 1 narcolepsy (NT1) by the China NMPA, as well as receiving breakthrough therapy designation from the FDA in the usa for the excessive daytime sleepiness associated with NT1.
Alkermes Raised to Buy by Stifel on Increased Confidence for ALKS2680
TD Cowen Maintains Takeda Pharmaceutical(TAK.US) With Buy Rating
Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript Summary
Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript
6-K: Semi-annual Securities Report